Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticlePractice

Health Canada advisory on domperidone

Should I avoid prescribing domperidone to women to increase milk production?

Pina Bozzo, Gideon Koren and Shinya Ito
Canadian Family Physician September 2012; 58 (9) 952-953;
Pina Bozzo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gideon Koren
MD FRCPC FACMT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinya Ito
MD FRCPC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

This article has a correction. Please see:

  • Correction - October 01, 2012

Abstract

Question I often prescribe domperidone to women as a galactagogue starting at a dose of 30 mg and increasing the dose as needed. In March of this year, Health Canada released an advisory warning of domperidone use and abnormal heart rhythms and sudden cardiac death. Should I cap doses at 30 mg or stop prescribing domperidone all together to these women?

Answer The Health Canada warning is based on 2 studies. The results of the studies are not directly applicable to breastfeeding and should not change the way you normally manage otherwise healthy breastfeeding women.

Domperidone is a dopamine antagonist with antiemetic and gastroprokinetic properties.1 It is indicated for the symptomatic management of upper gastrointestinal motility disorders and gastrointestinal symptoms associated with the use of dopamine agonist antiparkinsonian agents.1

Breastfeeding is recommended for all infants, with very few exceptions, as there are many benefits for the developing child, including evidence for improved cognitive development, reduced incidence of infection, and less risk of sudden infant death syndrome.2 Further, there is evidence of benefits for the mother, such as reduced incidence of reproductive cancers.3 Some women, however, experience insufficient breast milk production. Domperidone has been demonstrated to induce and maintain lactation by increasing prolactin levels.4 A recent systematic review and meta-analysis by Motherisk demonstrated a statistically significant increase of 74.7% (95% CI 54.6 to 94.9, P < .001) in daily milk production following treatment with domperidone and found no maternal safety issues when compared with placebo.5 At present, some intervention trials are under way to define the appropriate dose in specific populations (eg, mothers of preterm infants). Only minimal amounts of domperidone are excreted into breast milk (less than 0.1% of the maternal weight-adjusted dose), and side effects in breastfed infants have not been reported.3,6–8 Therefore, when nonpharmacologic treatments fail or are inadequate, domperidone might be an option.

Health Canada advisory

In March 2012 Health Canada released an advisory to health care professionals and to the public warning of possible serious side effects associated with the use of domperidone.9,10 The warning was based on 2 studies reporting an association of domperidone with serious abnormal heart rhythms and sudden cardiac death (SCD).11,12

In the first study, a nested case-control study by Johannes et al,11 domperidone use was associated with an increased risk of serious ventricular arrhythmia (SVA) and SCD when compared with nonusers (adjusted odds ratio [AOR] 1.59, 95% CI 1.28 to 1.98). The average age for the cohort was 79.4 years (range 20 to 95, median age 82); when stratified by age and sex, individuals younger than age 60 years and women did not have increased risk from domperidone exposure (OR [95% CI] 1.10 [0.35 to 3.47] and 1.25 [0.93 to 1.67], respectively).11

In the second study, a case-control analysis by van Noord et al,12 current domperidone use was associated with increased risk of SCD (unadjusted OR 3.72, 95% CI 1.72 to 8.08), but the AOR was not significant. When the authors further focused on publicly insured patients, which included 7 SCD cases with current domperidone use, the AOR became significant (AOR 4.17, 95% CI 1.33 to 13.1). Investigators were unable to demonstrate an effect of domperidone on SVA owing to an absence of exposed cases. When stratified by daily dose, doses above 30 mg/d were associated with higher risk of SCD (AOR 11.4, 95% CI 1.99 to 65.2). This association, however, was based on only 4 individuals exposed to domperidone who experienced SCD. Also of importance, the average (SD) age of the cohort of SCD cases (n = 1304) was 72.5 (14.1) years. Clearly, the populations in these studies are distinct from healthy breastfeeding women.12

Finally, in both studies, the data on the cases and controls were retrieved from databases. These databases have some limitations. One of the main limitations is that the researchers were only able to examine if a prescription for domperidone was filled. Whether or not the individual took the medication was not confirmed.11,12 Also, in the Netherlands, where the second study was conducted, domperidone is available over the counter; therefore, all exposures to domperidone might not have been captured.12

Conclusion

Owing to the demographic characteristics of the populations in both studies,11,12 the risks reported in these papers would not directly apply to healthy women of childbearing age. Nonetheless, caution is advised when prescribing domperidone with other drugs that prolong the QT interval or with those that interfere with domperidone metabolism, or for women who have underlying cardiac diseases.1

Notes

MOTHERISK

Motherisk questions are prepared by the Motherisk Team at the Hospital for Sick Children in Toronto, Ont. Ms Bozzo is Assistant Director, Dr Koren is Director, and Dr Ito is a member of the Motherisk Program. Dr Koren is supported by the Research Leadership for Better Pharmacotherapy during Pregnancy and Lactation. He holds the Ivey Chair in Molecular Toxicology in the Department of Medicine at the University of Western Ontario in London.

Do you have questions about the effects of drugs, chemicals, radiation, or infections in women who are pregnant or breastfeeding? We invite you to submit them to the Motherisk Program by fax at 416 813-7562; they will be addressed in future Motherisk Updates.

Published Motherisk Updates are available on the Canadian Family Physician website (www.cfp.ca) and also on the Motherisk website (www.motherisk.org).

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    Teva-domperidone [product monograph]. Toronto, ON: Teva Canada Ltd; 2012.
  2. ↵
    1. Health Canada
    . Nutrition for healthy term infants. Statement of the Joint Working Group: Canadian Paediatric Society, Dietitians of Canada, and Health Canada. Ottawa, ON: Health Canada; 2005. Available from: www.hc-sc.gc.ca/fn-an/pubs/infant-nourrisson/nut_infant_nourrisson_term-eng.php#a1. Accessed 2012 Apr 5.
  3. ↵
    1. Dermer A
    . A well-kept secret: breastfeeding’s benefits to mothers. New Beginnings. Vol. 18.(4) 2001. p. 124-7. Available from: www.llli.org/nb/nbjulaug01p124.html. Accessed 2012 Apr 5.
    OpenUrl
  4. ↵
    1. Petraglia F,
    2. De Leo V,
    3. Sardelli V,
    4. Pieroni ML,
    5. D’Antona N,
    6. Genazzani AR
    . Domperidone in defective and insufficient lactation. Eur J Obstet Gynecol Reprod Biol 1985;19(5):281-7.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Osadchy A,
    2. Moretti ME,
    3. Koren G
    . Effect of domperidone on insufficient lactation in puerperal women: a systematic review and meta-analysis of randomized controlled trials. Obstet Gynecol Int 2012;2012:642893. Epub 2012 Feb 7.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Jantarasaengaram S,
    2. Sreewapa P
    . Effects of domperidone on augmentation of lactation following cesarean delivery at full term. Int J Gynaecol Obstet 2012;116(3):240-3.
    OpenUrlCrossRefPubMed
    1. Hofmeyr GJ,
    2. Van Iddekinge B,
    3. Blott JA
    . Domperidone: secretion in breast milk and effect on puerperal prolactin levels. Br J Obstet Gynaecol 1985;92(2):141-4.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Da Silva OP,
    2. Knoppert DC,
    3. Angelini MM,
    4. Forret PA
    . Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo-controlled trial. CMAJ 2001;164(1):17-21.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Health Canada
    . Domperidone maleate—association with serious abnormal heart rhythms and sudden death (cardiac arrest)—for health care professionals. Ottawa, ON: Health Canada; 2012. Available from: http://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2012/domperidone_hpc-cps-eng.php. Accessed 2012 April 4.
  9. ↵
    1. Health Canada
    . Domperidone maleate—association with serious abnormal heart rhythms and sudden death (cardiac arrest)—for the public. Ottawa, ON: Health Canada; 2012. Available from: http://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/_2012/domperidone_pc-cp-eng.php. Accessed 2012 April 4.
  10. ↵
    1. Johannes CB,
    2. Varas-Lorenzo C,
    3. McQuay LJ,
    4. Midkiff KD,
    5. Fife D
    . Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf 2010;19(9):881-8.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Van Noord C,
    2. Dieleman JP,
    3. van Herpen G,
    4. Verhamme K,
    5. Sturkenboom MC
    . Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf 2010;33(11):1003-14.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 58 (9)
Canadian Family Physician
Vol. 58, Issue 9
1 Sep 2012
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Health Canada advisory on domperidone
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Health Canada advisory on domperidone
Pina Bozzo, Gideon Koren, Shinya Ito
Canadian Family Physician Sep 2012, 58 (9) 952-953;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Health Canada advisory on domperidone
Pina Bozzo, Gideon Koren, Shinya Ito
Canadian Family Physician Sep 2012, 58 (9) 952-953;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Health Canada advisory
    • Conclusion
    • Notes
    • Footnotes
    • References
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • Correction
  • PubMed
  • Google Scholar

Cited By...

  • A Survey of U.S. and Canadian Physicians Clinical Practices Related to Pharmacologic, Herbal, and Nutritional Substances Used to Increase Milk Production
  • A Review of Herbal and Pharmaceutical Galactagogues for Breast-Feeding
  • Postpartum domperidone use in British Columbia: a retrospective cohort study
  • Google Scholar

More in this TOC Section

Practice

  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
Show more Practice

Motherisk Update

  • Hepatitis A infection during pregnancy
  • Fluconazole use during breastfeeding
  • Is it safe to breastfeed while taking methylphenidate?
Show more Motherisk Update

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire